探讨不同强度抗凝治疗用于老年非瓣膜病慢性房颤患者治疗中的临床意义

Explore the Clinical Significance of Different Strength Anticoagulant Therapy in the Treatment of Elderly Patients with Non-valvular Disease Chronic Atrial Fibrillation

目的观察分析在老年非瓣膜病慢性房颤病患的治疗中采用不同强度抗凝治疗的临床治疗意义。方法选取非瓣膜病慢性房颤老年病患80例,将病患随机分为三组,其中一组病患给予华法林(INR1.5~2.0)进行抗凝治疗设为A组,共26例病患,一组病患给予华法林(INR2.01~2.5)进行抗凝治疗设为B组,共27例病患,最后一组病患给予华法林(INR2.51~3.0)进行抗凝治疗设为C组,共27例病患,对比两组病患的出血事件发生率、栓塞事件发生率。结果三组病患经治疗后,C组病患的栓塞事件明显低于A、B组病患(P<0.05);而C组病患的严重出血事件明显高于A、B组(P<0.05);但三组病患的总出血事件发生率比较无明显差异(P>0.05)。结论在老年非瓣膜病慢性房颤病患的治疗中维持INR为1.5~2.5,严重出血事件较低,可获得一定抗凝效果,值得推广。

Objective To observe and analyze the clinical significance of anticoagulation with different intensity in the treatment of elderly patients with non-valvular disease chronic atrial fibrillation.Methods Eighty elderly patients with non-valvular disease chronic atrial fibrillation were randomly divided into three groups.One group of patients was given warfarin(INR1.5~2.0)for anticoagulant treatment,which was set as group A,26 patients in total.One group of patients was treated with warfarin(INR2.01~2.5)for anticoagulation,which was set as group B,27 patients in total.The last group was treated with warfarin(INR2.51~3.0)for anticoagulation,which was set as group C,27 patients in total.The incidence of bleeding events and embolism events were compared between the two groups.Results After treatment,the embolization events in group C were significantly lower than those in groups A and B(P<0.05),while the serious bleeding events in group C were significantly higher than those in groups A and B(P<0.05),but there was no significant difference in the total bleeding events among the three groups(P>0.05).Conclusion In the treatment of elderly patients with non-valvular disease chronic atrial fibrillation,INR was maintained at 1.5~2.5,serious bleeding events were relatively low,and anticoagulation effect could be obtained,which is worth popularizing.